Literature DB >> 6831048

Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny.

J Cashman, D Henkelman, K Humphries, C Eaves, A Eaves.   

Abstract

Erythropoietic progenitors from peripheral blood of normal individuals or patients with polycythemia vera (PV) were cultured in methylcellulose medium containing 2.5 U/ml of erythropoietin (Ep). After 7-9 days, colonies considered to be early stage large bursts were individually removed, resuspended in a small volume of fresh methylcellulose medium, and then divided between 2 dishes. To one of these secondary cultures, sufficient Ep was added to bring the concentration of Ep up to approximately 3 U/ml. To the other was added an equal volume of medium but no Ep. The final concentration of Ep in these cultures was determined to be less than 0.01 U/ml. Nine days later, both types of secondary cultures were scored for the presence of colonies containing 8 or more hemoglobinized erythroblasts. Of 90 primary colonies from 3 normal individuals assessed in this way, 59 gave secondary erythroid colonies in the high Ep cultures, while none gave secondary erythroid colonies in the low Ep cultures. Additional control experiments in which primary colonies from normal individuals were divided into duplicate high Ep cultures showed that on average, the procedure used divided primary colonies equally. Of 109 primary colonies from 5 PV patients that yielded secondary erythroid colonies in the high Ep cultures, 21 yielded no secondary erythroid colonies in the low Ep cultures. The other 88 yielded erythroid colonies in both, but the secondary colonies in the low Ep cultures were consistently smaller in size and significantly fewer in number. Similar results were obtained when primary colonies were generated in cultures to which no Ep was added. These findings indicate that primitive BFU-E in patients with PV can be subdivided into 2 populations: a minor population restricted to the production of erythroid colony-forming cells (Ep-dependent progenitors) that require Ep for their detection, and a major population that is not restricted in this way. In addition, these experiments show that most of the primitive BFU-E that generate Ep-independent progenitors also produce significant numbers of cells that are Ep-dependent.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831048

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

2.  Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases.

Authors:  L Coulombel; C Eaves; D Kalousek; C Gupta; A Eaves
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

3.  Interleukin 3 promotes erythroid burst formation in "serum-free" cultures without detectable erythropoietin.

Authors:  J W Goodman; E A Hall; K L Miller; S G Shinpock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

4.  Characterization of a virus that causes transient aplastic crisis.

Authors:  N S Young; P P Mortimer; J G Moore; R K Humphries
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

Review 5.  Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.

Authors:  Sabine Blum; Filipe Martins; Lorenzo Alberio
Journal:  J Blood Med       Date:  2016-09-23

6.  Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.

Authors:  J G Moore; M M Frank; H J Müller-Eberhard; N S Young
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

7.  Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.